MarketCap
Facebook
X
Telegram
Merrimack Pharmaceuticals Cash Conversion Cycle | MACK
Annual Cash Conversion Cycle Merrimack Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 645 | -10.5 K | 18.1 | 57.8 | 62.3 | 39.6 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 645 | -10.5 K | -1.61 K |
Quarterly Cash Conversion Cycle Merrimack Pharmaceuticals
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 329 | 981 | 367 | 338 | -1.45 K | 36 | 16.2 | 30.1 | 8.92 | 10.8 | 10.9 | 32.1 | 68.3 | 78 | 29 | 47.1 | 59.6 | 74.7 | 70.1 | 67.1 | 53.9 | 79 | 103 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 981 | -1.45 K | 62.6 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
-1.55 K | $ 5.32 | 0.09 % | $ 652 M |  USA |
 |
ADC Therapeutics SA
ADCT
|
-543 | $ 1.05 | 0.46 % | $ 133 M |  Schweiz |
 |
Agenus
AGEN
|
-25.8 K | $ 7.21 | 0.7 % | $ 214 M | USA |
 |
Фармсинтез
LIFE
|
-15.9 | - | - | - |  Russia |
 |
Akebia Therapeutics
AKBA
|
42 | $ 0.92 | 1.64 % | $ 237 M | USA |
 |
Alector
ALEC
|
-13.8 | $ 1.93 | 0.81 % | $ 199 M | USA |
 |
Alkermes plc
ALKS
|
299 | $ 46.07 | 0.09 % | $ 7.59 B |  Irlanda |
 |
Alnylam Pharmaceuticals
ALNY
|
31.7 | $ 239.36 | 0.46 % | $ 31.4 B | USA |
 |
Altimmune
ALT
|
7.85 K | $ 3.24 | 0.31 % | $ 285 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
205 | $ 23.95 | 1.31 % | $ 1.12 B | USA |
 |
AnaptysBio
ANAB
|
58 | $ 54.31 | 0.15 % | $ 1.56 B | USA |
 |
Anika Therapeutics
ANIK
|
192 | $ 20.84 | 0.24 % | $ 299 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
196 | $ 73.59 | 2.05 % | $ 1.48 B | USA |
 |
Aptevo Therapeutics
APVO
|
-47.4 | $ 1.72 | 0.58 % | $ 543 K | USA |
 |
Aquestive Therapeutics
AQST
|
-172 | $ 4.82 | 0.21 % | $ 515 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
21.2 | $ 15.6 | 0.25 % | $ 427 M |  Israel |
 |
Assembly Biosciences
ASMB
|
2.46 | $ 25.48 | 0.54 % | $ 286 M | USA |
 |
AbbVie
ABBV
|
284 | $ 262.51 | 0.01 % | $ 464 B | USA |
 |
Atara Biotherapeutics
ATRA
|
4.13 | $ 10.11 | 7.1 % | $ 127 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
612 | $ 16.96 | 5.15 % | $ 2.28 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
119 | $ 1.87 | 0.53 % | $ 498 M |  Britain |
 |
Axon Enterprise
AXON
|
64.5 | $ 468.42 | 5.96 % | $ 36.6 B | USA |
 |
Axsome Therapeutics
AXSM
|
-256 | $ 211.97 | 3.87 % | $ 10.5 B | USA |
 |
Aytu BioScience
AYTU
|
174 | $ 1.97 | 0.5 % | $ 12.4 M | USA |
 |
BridgeBio Pharma
BBIO
|
-114 | $ 68.3 | 0.1 % | $ 13.1 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
13.8 | $ 3.64 | 0.68 % | $ 252 M | Britain |
 |
Biogen
BIIB
|
337 | $ 216.01 | 0.42 % | $ 31.6 B | USA |
 |
AbCellera Biologics
ABCL
|
173 | $ 11.67 | 2.28 % | $ 3.49 B | Canada |
 |
Benitec Biopharma
BNTC
|
141 | $ 11.04 | 0.9 % | $ 514 M | USA |
 |
Clovis Oncology
CLVS
|
271 | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
52.5 | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
5.06 | - | - | $ 401 M | USA |
 |
Catalyst Biosciences
CBIO
|
285 | $ 17.18 | 1.7 % | $ 1.53 B | USA |
 |
C4 Therapeutics
CCCC
|
27.9 | $ 3.45 | 0.58 % | $ 286 M | USA |